Standard drug could cure leukaemia

John von Radowitz
Wednesday 20 October 2010 00:00 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Some leukaemia patients could be cured of their disease by a standard drug treatment, new trial results suggest.

A proportion of patients with chronic myeloid leukaemia (CML) remained completely free of the disease two years after doctors stopped treating them with the drug imatinib, trial results indicated.

It had been believed that the disease would always return if treatment was halted, due to the presence of resistant stem cells.

Glivec, the standard treatment for CML, a slow-growing, long-term form of leukaemia, works by switching off an enzyme linked to the cancer, leading to reduced levels of an abnormal protein called BCR/ABL.

In some patients, imatinib can produce complete molecular remission (CMR), marked by the protein becoming undetectable.

The scientists, led by Professor Francois-Xavier Mahon, from Victor Segalen Bordeaux University in France, reported their findings in the journal The Lancet Oncology.

However, the authors pointed out that sustained complete molecular remission – the prerequisite for stopping treatment – did not often occur. Suitable candidates for treatment stoppage might represent only about 10 per cent of patients.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in